摘要：The healthcare industry is a large and fast-growing segment of the corporate world, especially in developed countries. In the face of growing competition, healthcare companies inevitably resort to mergers and acquisitions (MAs) in order to accelerate their development. The objective of this study is to identify the creation of additional value for MA deal participants in the healthcare industry in the United States and the European Union in 2008-2017. In this paper, we propose the following thesis statement: can healthcare companies expect excess returns from MA deals? On average, MA deals in the healthcare industry in developed countries create positive abnormal returns for acquiring companies and are efficient; a positive, significant impact on abnormal returns was found in the deal value of MA deals, a negative significant impact was observed for deals conducted with the shares payment method and for acquiring companies with a larger number of employees.
